Exparel 266 MG/20 ML vial 20ML
Ended Awarded Last action
- Contract number
- SPE2DR26FCFR4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $17,971
Award facts
- Contract value 100% obligated
- $17,971.24 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $17,971.24 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, on January 29, 2026. The delivery order is for EXPAREL 266 mg/20 mL vials, a specialty surgical anesthetic product, with an ultimate completion date of February 20, 2026. No set-aside designation was used for this award. This delivery order was issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract (IDC) with the Defense Logistics Agency, designated as contract SPE2DR under the Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, which carries a $499.9 billion ceiling value through December 31, 2036.
The PPV-G GEN V program represents a comprehensive $30.3 billion acquisition strategy designed to support the Department of Defense's recurring pharmaceutical and medical supply needs across military healthcare facilities worldwide. DMS Pharmaceutical Group's role as a regional prime vendor contractor positions the company to supply a diverse portfolio of pharmaceuticals, including branded and generic prescription medications, biologics, vaccines, and specialty surgical products, to support military medical operations. The company's established performance on numerous prior delivery orders demonstrates its capability to fulfill the specialized pharmaceutical requirements of the federal military medical system. No subcontractors were identified in the award documentation.
Quick answers
Who was awarded contract SPE2DR26FCFR4?
SPE2DR26FCFR4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 29, 2026.
How much is contract SPE2DR26FCFR4 worth?
The government has obligated $17,971 on SPE2DR26FCFR4.
Is contract SPE2DR26FCFR4 an order under another contract?
Yes. SPE2DR26FCFR4 is a delivery order under SPE2DR25D9133, an indefinite delivery contract.
Was contract SPE2DR26FCFR4 competed?
The extent of competition for SPE2DR26FCFR4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award